Not recruiting yet
Totally Versus Hybrid Minimally Invasive Esophagectomy for Esophageal Cancer
NCT07408999 · University Hospital, Lille · Updated 13 Feb 2026
- What is being tested
- Totally Minimally Invasive Esophagectomy (TMIE); Hybrid Esophagectomy (HE)
- For
- Resecable Esophageal or Gastroesophageal Junction Cancer
- Kind of study
- Tests a treatment or device on volunteers. No drug phase (a device or procedure study).
- Who can join
- Ages 18 years to 80 years. About 327 people. The full rules are on the registry page.
- Where
- France
- When
- Starts or started 31 March 2026, ends 31 March 2031. Registered 13 Feb 2026.
- Results
- None posted yet.
In the researchers' words
Esophageal and gastroesophageal junction cancers remain associated with poor survival despite progress in multimodal treatment. Surgery, especially Ivor-Lewis esophagectomy, combined with peri-operative therapy improves survival but is burdened by major morbidity, mainly respiratory and anastomotic complications, which compromise recovery and adjuvant treatment. Minimally invasive approaches such as totally minimally invasive esophagectomy (TMIE) have shown potential to reduce postoperative morbidity compared to the hybrid approach (HE). However, existing studies are heterogeneous, mostly retrospective, and insufficient to establish a standard. This trial aims to provide high-level evidence comparing TMIE to HE, including robotic techniques, with integrated analyses of clinical outcomes, quality of life, and health economics.
Sites
- CHU de LilleLille, France
